Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Harvard Business School
McKinsey
Julphar
Chinese Patent Office
US Department of Justice
Express Scripts
Chubb
McKesson

Generated: April 26, 2018

DrugPatentWatch Database Preview

NARATRIPTAN Drug Profile

« Back to Dashboard

Which patents cover Naratriptan, and when can generic versions of Naratriptan launch?

Naratriptan is a drug marketed by Apotex Corp, Casi Pharms Inc, Heritage Pharms Inc, Mylan Pharms Inc, Orchid Hlthcare, Paddock Llc, Sun Pharm Inds Ltd, Teva Pharms, and West-ward Pharms Int. and is included in nine NDAs.

The generic ingredient in NARATRIPTAN is naratriptan hydrochloride. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the naratriptan hydrochloride profile page.
Drug patent expirations by year for NARATRIPTAN
Synonyms for NARATRIPTAN
10X8X4P12Z
143388-64-1
1H-Indole -5-ethanesulfonamide,N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride
1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride
2-[3-(1-methyl-piperidin-4-yl)-1H-indol-5-yl]-ethanesulfonic acid methylamide Hydrochloride
388N641
A808063
AB0033380
ABP001029
AC-5014
AC1L1U3C
AC1Q3ETY
AK398843
AKOS005145806
Amerge
Amerge (TN)
AN-5269
API0000686
AT-19354
AWEZYKMQFAUBTD-UHFFFAOYSA-N
C17H25N3O2S.HCl
CAS-143388-64-1
CCG-221770
CHEBI:7479
CHEMBL1200601
CS-2132
CTK8E8530
D00674
DSSTox_CID_28990
DSSTox_GSID_49064
DSSTox_RID_83255
DTXSID6049064
FT-0672649
GG-548
GR 85548A
GR-85548A
HY-B0197A
J-007804
KS-00000OQE
LS-172502
MFCD08141821
MLS006010726
MolPort-003-849-333
N-methyl-2-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)ethanesulfonamide hydrochloride
N-methyl-2-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]ethanesulfonamide hydrochloride
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]ethanesulfonamide Hydrochloride
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide hydrochloride
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide;hydrochloride
N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide hydrochloride
n-methyl-3-(1-methyl-4-piperidinyl)-1h-indole-5-ethanesulphonamide hydrochloride
N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide, hydrochloride
N-Methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride
Naramig
Naratriptan (hydrochloride)
Naratriptan HCl
NARATRIPTAN HYDROCHLORIDE
Naratriptan hydrochloride (JAN/USAN)
Naratriptan hydrochloride [USAN:USP]
Naratriptan hydrochloride [USAN]
Naratriptan hydrochloride, >=98% (HPLC)
Naratriptan hydrochloride, United States Pharmacopeia (USP) Reference Standard
naratriptanhydrochloride
NCGC00181786-01
NCGC00181786-02
NCGC00261151-01
PubChem16865
Q-201448
QCR-255
RB3224
RTC-070946
s1488
SCHEMBL41527
SMR002529694
TC-070946
Tox21_113617
Tox21_113617_1
Tox21_500466
UNII-10X8X4P12Z
VA11356
X6918

US Patents and Regulatory Information for NARATRIPTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Corp NARATRIPTAN naratriptan hydrochloride TABLET;ORAL 091373-001 Apr 22, 2011 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc NARATRIPTAN naratriptan hydrochloride TABLET;ORAL 202431-001 May 31, 2012 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Casi Pharms Inc NARATRIPTAN naratriptan hydrochloride TABLET;ORAL 090288-002 Jul 7, 2010 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Paddock Llc NARATRIPTAN naratriptan hydrochloride TABLET;ORAL 091326-002 Jul 8, 2010 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Citi
Deloitte
Medtronic
Covington
Boehringer Ingelheim
Federal Trade Commission
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.